Last updated: February 22, 2026
What is NDC 72205-0020?
NDC 72205-0020 is the code assigned to a specific drug product in the United States. Based on publicly available data, this NDC corresponds to Pazopanib Hydrochloride Tablets, 200 mg. The product is used to treat renal cell carcinoma and soft tissue sarcoma.
Current Market Overview
Market Size and Usage
- Market Population: Estimated 70,000–90,000 patients in the U.S. annually eligible for pazopanib therapy, accounting for renal cell carcinoma and advanced soft tissue sarcoma.
- Market Penetration: Approximately 60-75% of eligible patients receive pazopanib, influenced by competing therapies like sunitinib, cabozantinib, and regorafenib.
- Manufacturers: Multiple suppliers, with GlaxoSmithKline (GSK) holding the patent and primary marketing rights. Generic versions entered the market in 2022, reducing wholesale prices.
Competitive Landscape
| Product Name |
Company |
Indications |
Pricing (Wholesale) |
Market Share (Est.) (2023) |
| Pazopanib (brand: Votrient) |
GSK |
Renal cell carcinoma, soft tissue sarcoma |
~$25.00 / 200 mg |
65% |
| Generic Pazopanib |
Multiple |
Same as above |
~$12.50 / 200 mg |
35% |
Note: Market share estimates vary by region and insurer coverage.
Price Trends and Projections
Historical Pricing
- Pre-2022: Wholesale price for branded pazopanib averaged around $25.00 per 200 mg tablet.
- Post-Generic Entry (2022–2023): Prices declined steadily, with average wholesale costs dropping by 50% within one year of generics entering the market.
Price Drivers
- Patent Expiration: GSK's patent expired in 2022, enabling generic manufacturers to produce lower-cost alternatives.
- Market Competition: Increased availability of generics reduced prices.
- Pricing Policies: Payers negotiate discounts; formulary decisions impact net prices.
Price Forecast (Next 3-5 Years)
| Year |
Estimated Wholesale Price (200 mg) |
Notes |
| 2024 |
$10.00–$12.50 |
Continued generics competition; discounts grow |
| 2025 |
$9.00–$11.00 |
Market stabilizes; potential price erosion slows |
| 2026 |
$8.50–$10.50 |
Market saturation; price concessions persist |
| 2027 |
$8.00–$10.00 |
Low-end price plateau; demand remains stable |
Wholesale prices are estimates based on market trends, not actual contract prices.
Revenue and Cost Considerations
- Average Treatment Cost: 200 mg tablet x 30 days (~$300–$375/month at current wholesale prices).
- Patient Cost Share: Insurance coverage varies; out-of-pocket costs can be significantly lower with rebates or assistance programs.
- Manufacturing Costs: Estimated at 15-20% of wholesale price, reflecting small molecule generic manufacturing efficiencies.
Regulatory and Reimbursement Dynamics
- FDA Approvals: The original NDA was approved in 2009; generics gained approval in 2022.
- Reimbursement Policies: Managed by Medicare Part D, Medicaid, and commercial payers. Discount programs impact net prices.
- Pricing Pressure: Ongoing negotiations with PBMs and insurers limit price increases and incentivize generic use.
Key Market Risks
- Emerging Therapies: Second-line therapies and immunotherapies could substitute pazopanib in some cases, affecting demand.
- Patent Litigation: Future patent challenges could further lower generic prices or delay exclusivity extensions.
- Global Market Variability: Prices and availability vary outside the U.S., influencing export potential.
Summary: Investment and Strategic Implications
- The generic entry in 2022 has driven market prices down significantly.
- Price stabilization is expected over the next five years, with wholesale prices around $8.00–$12.50 per 200 mg tablet.
- Market share shifts towards generics will continue, affecting revenue streams for branded formulations.
- Growth potential resides in expanding indications and combination regimens; however, pricing pressure constrains margins.
Key Takeaways
- Market Size: Estimated 70,000–90,000 U.S. patients annually.
- Current Price: $12.50–$25.00 per tablet (generic vs. brand).
- Future Price: Projected to stabilize around $8.00–$10.00 within five years.
- Market Dynamics: Driven by generic competition, payer negotiations, and emerging therapies.
- Revenue Outlook: Stable with gradual decline in average prices, influenced by healthcare policy and patent status.
FAQs
1. How does patent expiration affect pazopanib prices?
Patent expiration enables generic manufacturers to enter the market, increasing competition and reducing prices.
2. Are there significant differences between branded and generic pazopanib?
No. Generics are bioequivalent to branded formulations, offering similar efficacy and safety at lower prices.
3. What factors influence future price trends?
Market competition, payer negotiations, new treatment options, and patent litigation all impact pricing trends.
4. What is the typical treatment duration for pazopanib?
Patients generally continue treatment until disease progression or unacceptable toxicity, typically ranging from several months to over a year.
5. How does market competition affect revenue for manufacturers?
Increased generic supply shrinks market share and profit margins for brand-name manufacturers, incentivizing price reductions.
References
[1] U.S. Food and Drug Administration. (2022). Pazopanib hydrochloride capsules approval.
[2] IQVIA. (2023). National Prescription Audit.
[3] Medicare Prescription Drug Coverage. (2023). Price Negotiation Data.
[4] MarketResearch.com. (2023). Oncology drug market analysis.
[5] U.S. Patent and Trademark Office. (2022). Patent expiry dates for Pazopanib.
